
NGEN Stock Forecast & Price Target
NGEN Analyst Ratings
Bulls say
NervGen Pharma is in a strong financial position with the recent completion of a $60M financing round, providing significant support for their lead candidate NVG-291. With promising early clinical results and plans to present data from their trial in the second half of 2026, the company is on track for potential FDA approval and commercialization of NVG-291 in 2029, leading to potential increased operating expenses and potential acquisition. In addition, NervGen's strong intellectual property protection secures a well-protected commercial window for their products, further highlighting their potential for success in the neuroreparative therapeutics sector.
Bears say
NervGen Pharma is a clinical-stage biopharmaceutical company currently developing neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Despite promising results in their Phase 1b/2a trials and upcoming enrollment for their pivotal Phase 3 study, there are significant risks to achieving their estimated market value and price objective of $18 per share by 2026. These risks include potential delays in starting the pivotal trial, negative results from the Phase 3 program, and slower-than-expected sales uptake for their lead candidate, NVG-291. Additionally, the company has a small cash reserve and may require additional capital to complete pivotal development of NVG-291. With competition from larger firms and the uncertain nature of clinical trials, there is no guarantee of future success.
This aggregate rating is based on analysts' research of NervGen Pharma Corp and is not a guaranteed prediction by Public.com or investment advice.
NGEN Analyst Forecast & Price Prediction
Start investing in NGEN
Order type
Buy in
Order amount
Est. shares
0 shares